Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer Tamoxifen, which is ...
At the virtual San Antonio Breast Cancer Symposium, researchers presented 12-year results for tamoxifen versus anastrozole [Arimidex], which demonstrated no significant difference in terms of disease ...
4th European Breast Cancer Conference - Hamburg, Germany. March 17 2004: New data presented today 1,2, indicate that preoperative (neoadjuvant) treatment with ARIMIDEX TM (anastrozole) results in ...
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial concluded that anastrozole was more effective than tamoxifen in preventing recurrence of breast cancer. The ATAC Trialists' Group recently ...
SAN ANTONIO ― Oncologists can now offer postmenopausal women with ductal carcinoma in situ (DCIS) two options for prevention of breast cancer recurrence: anastrozole (Arimidex, AstraZeneca ...
HER2/neu expression to be determined by quality-controlled assays using immunohistochemistry or FISH analysis. ER: Estrogen receptor; PgR: Progesterone receptor ...
Previous use of hormone replacement therapy (HRT), hormone-receptor positivity, previous chemotherapy, obesity, and treatment with anastrozole versus tamoxifen are all risk factors for joint symptoms ...
AstraZeneca is still basking in the glow of data from one of the world’s largest breast cancer trials which highlights the benefits of the firm’s Arimidex over tamoxifen in preventing all forms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback